NUDT15 rs34059508: What Your Genotype Means
The rs34059508 variant is a genetic change located within the NUDT15 gene that is associated with how the body processes a class of medications called thiopurines. This variant is recognized for its potential to influence drug tolerance, particularly in patients undergoing treatment for conditions like pediatric leukemia.
What each genotype means
Normal enzyme activity
This genotype represents the most common form of the NUDT15 gene, which is typically associated with normal metabolism of thiopurine medications. Individuals with this profile are generally expected to tolerate standard dosing of these drugs, though clinical monitoring remains standard practice. Please discuss your medication plan and any concerns about drug side effects with your healthcare provider.
This is the most common genotype observed across all global populations.
Reduced enzyme activity
This genotype indicates the presence of one copy of the variant allele, which may lead to reduced NUDT15 enzyme activity and potentially increased sensitivity to thiopurine medications. Research suggests that carriers of this variant may be at a higher risk for treatment-related toxicity, such as myelosuppression, compared to those without the variant. It is essential to consult with your clinician or pharmacist regarding appropriate dosing strategies if you are prescribed thiopurines.
This genotype is found in approximately 1-3% of individuals in East Asian and Southeast Asian populations, with varying frequencies in other global groups.
Significantly reduced enzyme activity
This genotype indicates the presence of two copies of the variant allele, which is associated with a significant reduction or loss of NUDT15 enzyme function. Individuals with this profile are at a substantially higher risk for severe thiopurine-induced toxicity, including life-threatening myelosuppression, if treated with standard medication doses. You must discuss this genetic finding with your healthcare provider before starting any thiopurine therapy to ensure safe and personalized dosing.
This genotype is rare, occurring in approximately 1 in every 50 individuals of East Asian descent, and is less common in other populations.
Understanding the rs34059508 Variant
The rs34059508 variant is a specific change in the DNA sequence of the NUDT15 gene, which stands for Nudix Hydrolase 15. In genetic terms, this is a missense variant, meaning it results in a single amino acid substitution—specifically, a change from valine to isoleucine at position 18 (p.Val18Ile). This variant is a defining component of the NUDT15*2 haplotype. Genetic variants like this are studied in the field of pharmacogenomics, which examines how an individual's unique genetic makeup affects their response to drugs. Because this variant can alter the function of the NUDT15 enzyme, researchers monitor it to understand why some individuals may experience different therapeutic outcomes or side effects when prescribed thiopurine medications.
The Role of the NUDT15 Gene
The NUDT15 gene provides instructions for creating an enzyme that plays a critical role in the metabolic pathway of thiopurines, such as mercaptopurine and azathioprine. These drugs are commonly used to treat acute lymphoblastic leukemia and various inflammatory conditions. The NUDT15 enzyme acts as a regulator by breaking down active thiopurine metabolites, thereby preventing the accumulation of toxic substances that could damage DNA or cause cellular harm. When the NUDT15 gene carries functional variants, the resulting enzyme may have reduced activity. This reduction can lead to an accumulation of active drug metabolites in the body, which is associated with an increased risk of myelosuppression—a condition where bone marrow activity decreases, leading to lower blood cell counts, such as leukopenia or neutropenia.
Research and Clinical Evidence
Research into NUDT15 variants has grown significantly, as these genetic markers explain a portion of the variability in thiopurine-related toxicity that cannot be accounted for by other genes like TPMT. While the evidence linking certain NUDT15 variants to severe hematotoxicity is strong, the specific clinical impact of rs34059508 is often categorized as having limited or evolving evidence compared to more well-characterized variants. Studies suggest that individuals carrying variants that reduce NUDT15 function may require closer monitoring or dose adjustments to avoid adverse effects. However, clinical guidelines emphasize that genetic testing is only one piece of the puzzle. Clinicians must integrate genetic information with other clinical factors, such as blood counts and disease severity, to make informed decisions about medication dosing.
Population Frequency and Distribution
The frequency of the rs34059508 variant varies significantly across different global populations. Current data indicates that this variant is most frequently observed in East Asian and Southeast Asian populations, with a minor allele frequency typically ranging between 1% and 3%. In contrast, this variant is much less common or virtually absent in populations of African or European ancestry. This ancestral distribution is a key focus of pharmacogenomic research, as it highlights why certain populations may have a higher prevalence of specific drug-metabolizing phenotypes. Understanding these frequency differences helps healthcare providers anticipate the likelihood of encountering these variants in specific patient groups, though individual testing remains the only way to confirm a person's specific genotype.
Navigating Your Genetic Information
If you have received information about your NUDT15 genotype, it is important to understand that this data is for educational purposes and does not constitute a medical diagnosis. Genetic variants are just one factor that influences how your body responds to medication. You should never change your medication dosage or stop taking a prescribed treatment based on genetic test results without first consulting your doctor or a clinical pharmacist. These professionals are trained to interpret genetic data in the context of your overall health, medical history, and current treatment plan. If you are concerned about potential side effects from thiopurine therapy, discuss your genetic profile with your healthcare team; they can provide guidance on whether dose adjustments or alternative monitoring strategies are appropriate for your specific situation.
How common is this variant?
The rs34059508 variant is a low-frequency missense variant with a minor allele frequency of approximately 1-3% in East Asian and Southeast Asian populations.
Frequently asked questions
What does it mean to be a poor metabolizer of thiopurines?
A poor metabolizer has reduced activity of enzymes like NUDT15 or TPMT, which are responsible for breaking down thiopurine drugs. This can lead to higher levels of the drug in the body, increasing the risk of side effects like bone marrow suppression.
Should I get tested for NUDT15 variants before starting medication?
Clinical guidelines often recommend testing for NUDT15 and TPMT variants before starting thiopurine therapy to help guide initial dosing. You should discuss the necessity and benefits of this testing with your prescribing physician.
Is rs34059508 the only variant that affects thiopurine response?
No, there are several other variants in the NUDT15 and TPMT genes that can influence how your body processes thiopurines. A comprehensive clinical assessment considers multiple genetic and non-genetic factors.
Can I change my medication dose based on my NUDT15 result?
No, you should never change your medication dosage on your own. Any adjustments to your treatment plan must be made by your doctor, who will consider your genetic results alongside your clinical symptoms and blood test results.
Sources & further reading
Educational information only, last refreshed 10/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs34059508?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in NUDT15
This variant is often confused with the primary NUDT15*3 (p.Arg139Cys) variant, which is rs116855232. rs116822326 is a distinct NUDT15 variant.
Splice/intronic regulatory modifier in NUDT15 associated with reduced enzyme level and enhanced susceptibility to thiopurine-induced severe leukopenia.
The NUDT15 p.Arg139Cys variant (defining the *3 allele) is a major determinant of thiopurine-induced myelosuppression.
NUDT15 c.55_56insGAGTCG (p.Val18_Gly19insGlyVal) defining the NUDT15*6 allele, associated with reduced enzyme activity and increased risk of thiopurine-induced leukopenia.
This variant is a defining marker for NUDT15 star alleles (*2, *6, *9) which are critical for predicting thiopurine-induced toxicity.
This variant (NUDT15 *3) is the primary predictor of severe, life-threatening bone marrow toxicity when taking thiopurine drugs.